Tus-Pharmaceutical Group Co., Ltd.

Equities

000590

CNE000000701

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
6.64 CNY -0.90% Intraday chart for Tus-Pharmaceutical Group Co., Ltd. -3.91% -25.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tus Pharmaceutical to Boost Investment in Chemical Park Project MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 55% stake in Wuhan Medtek Pharmaceutical Co., Ltd. from Tan Yunliang and Wang Zhong for approximately CNY 140 million. CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments CI
Tus Pharmaceutical to Set Up New Marketing Subsidiary MT
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guhan Traditional Chinese Medicine Co., Ltd. announced that it expects to receive CNY 22 million in funding from Tus-Pharmaceutical Group Co., Ltd. CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tus-Pharmaceutical Group Co., Ltd. completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang. CI
Tus Pharmaceutical to Buy Local Drugmaker Xiantong for $33 Million MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang fron CNY220 million. CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hunan Tus-Pharmaceutical Biological Co., Ltd. announced that it expects to receive CNY 25 million in funding from Tus-Pharmaceutical Group Co., Ltd., Ningbo Yiduoduo Electronic Commerce Co., Ltd. CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Tus Pharmaceutical : Adopts New Name MT
Tus-Guhan Group Corp.,Ltd. Approves Board Elections CI
Tus-Guhan Group Corp.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Chart Tus-Pharmaceutical Group Co., Ltd.
More charts
Tus Pharmaceutical Group Co Ltd, formerly Tus-Guhan Group Corp Ltd, is principally engaged in the manufacture and sale of pharmaceuticals. The Company provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. It also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The Company distributes its products in domestic markets.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW